drugset / Trial / NCT05655949
Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio
Phase 2
Recruiting
30 enrolled
Beth Israel Deaconess Medical Center
Dana-Farber Cancer Institute · collabSirtex Medical · collab
NaSingle-groupOpen-labelTreatment
Summary
This trial is designed to study a combination of interventions (chemotherapy, immunotherapy, and radiation) as a potential new treatment for bile duct cancer that cannot be removed with surgery. The specific names of the interventions that will be used are: * Y-90 (a type of radiation microsphere bead) * Durvalumab (a type of immunotherapy) * Gemcitabine (a type of chemotherapy) * Cisplatin (a type of chemotherapy)
Timeline
- Start
- 2024-02-13
- Primary completion
- 2026-12-01
- Completion
- 2027-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | Intravenous |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Gemcitabine | Small molecule | — | Intravenous |